Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Kaller A, Veale D, Yee H, Skupinska K, Wauthy R, Wang L, Baird I, Zhu Y, Burrage K, Yang W, Sartori M, Huskens D, De Clercq E, Schols D. Skerlj R, et al. Among authors: veale d. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1414-8. doi: 10.1016/j.bmcl.2011.01.021. Epub 2011 Jan 11. Bioorg Med Chem Lett. 2011. PMID: 21295470
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D. Skerlj RT, et al. Among authors: veale d. J Med Chem. 2010 Apr 22;53(8):3376-88. doi: 10.1021/jm100073m. J Med Chem. 2010. PMID: 20297846
Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.
Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Wilson T, Veale D, Yee H, Crawford J, Skupinska K, Wauthy R, Yang W, Zhu Y, Bogucki D, Di Fluri M, Langille J, Huskens D, De Clercq E, Schols D. Skerlj R, et al. Among authors: veale d. Bioorg Med Chem Lett. 2011 Jan 1;21(1):262-6. doi: 10.1016/j.bmcl.2010.11.023. Epub 2010 Nov 6. Bioorg Med Chem Lett. 2011. PMID: 21109432
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Langille J, Harwig C, Veale D, Yang W, Li T, Zhu Y, Bey M, Baird I, Sartori M, Metz M, Mosi R, Nelson K, Bodart V, Wong R, Fricker S, Mac Farland R, Huskens D, Schols D. Skerlj R, et al. Among authors: veale d. Bioorg Med Chem Lett. 2011 Dec 1;21(23):6950-4. doi: 10.1016/j.bmcl.2011.09.133. Epub 2011 Oct 8. Bioorg Med Chem Lett. 2011. PMID: 22033460
Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D. Skerlj R, et al. Among authors: veale d. J Med Chem. 2013 Oct 24;56(20):8049-65. doi: 10.1021/jm401101p. Epub 2013 Oct 3. J Med Chem. 2013. PMID: 24090135
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Danthi S, Langille J, Harwig C, Veale D, Carpenter B, Ba T, Bey M, Baird I, Wilson T, Metz M, MacFarland R, Mosi R, Bodart V, Wong R, Fricker S, Huskens D, Schols D. Skerlj R, et al. Among authors: veale d. ACS Med Chem Lett. 2012 Jan 25;3(3):216-21. doi: 10.1021/ml2002604. eCollection 2012 Mar 8. ACS Med Chem Lett. 2012. PMID: 24900457 Free PMC article.
CD200+ fibroblasts form a pro-resolving mesenchymal network in arthritis.
Rauber S, Mohammadian H, Schmidkonz C, Atzinger A, Soare A, Treutlein C, Kemble S, Mahony CB, Geisthoff M, Angeli MR, Raimondo MG, Xu C, Yang KT, Lu L, Labinsky H, Saad MSA, Gwellem CA, Chang J, Huang K, Kampylafka E, Knitza J, Bilyy R, Distler JHW, Hanlon MM, Fearon U, Veale DJ, Roemer FW, Bäuerle T, Maric HM, Maschauer S, Ekici AB, Buckley CD, Croft AP, Kuwert T, Prante O, Cañete JD, Schett G, Ramming A. Rauber S, et al. Among authors: veale dj. Nat Immunol. 2024 Apr;25(4):682-692. doi: 10.1038/s41590-024-01774-4. Epub 2024 Feb 23. Nat Immunol. 2024. PMID: 38396288
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: veale d. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
603 results